诊断学理论与实践 ›› 2018, Vol. 17 ›› Issue (02): 211-215.doi: 10.16150/j.1671-2870.2018.02.018
赵思达1, 赵佑山1, 常春康1, 肖志坚2
收稿日期:2017-07-17
出版日期:2018-04-25
发布日期:2018-04-25
通讯作者:
常春康 E-mail: changchunkang7010@aliyun.com;肖志坚 E-mail: zjxiao@hotmail.com
基金资助:
Received:2017-07-17
Online:2018-04-25
Published:2018-04-25
中图分类号:
赵思达, 赵佑山, 常春康, 肖志坚. 慢性粒单核细胞白血病的诊断进展[J]. 诊断学理论与实践, 2018, 17(02): 211-215.
| [1] Arber DA, Orazi A, Hasserjian R, et al.he 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405. [2] Bennett JM, Catovsky D, Daniel MT, et al.Proposals for the classification of the myelodysplastic syndromes[J]. Br J Haematol,1982,51(2):189-199. [3] Guru Murthy GS, Dhakal I, Mehta P.Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States[J]. Leuk Lymphoma,2017,58(7):1648-1654. [4] Srour SA, Devesa SS, Morton LM, et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12[J]. Br J Haematol,2016,174(3):382-396. [5] Solary E, Itzykson R.How I treat chronic myelomonocy-tic leukemia[J]. Blood,2017,130(2):126-136. [6] Patnaik MM, Tefferi A.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management[J]. Am J Hematol,2016,91(6):631-642. [7] Pophali PA, Patnaik MM.The role of new tyrosine kinase inhibitors in chronic myeloid leukemia[J]. Cancer J,2016, 22(1):40-50. [8] Patnaik MM, Lasho TL, Finke CM, et al.Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis[J]. Am J Hematol,2016,91(3):E12-E14. [9] Bain BJ.What is a promonocyte?[J]. Am J Hematol,2013,88(10):919. [10] Tang G, Zhang L, Fu B, et al.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution[J]. Am J Hematol,2014, 89(8):813-818. [11] Such E, Cervera J, Costa D, et al.Cytogenetic risk stratification in chronic myelomonocytic leukemia[J]. Haematologica,2011,96(3):375-383. [12] Patnaik MM, Itzykson R, Lasho TL, et al.ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients[J]. Leukemia,2014,28(11):2206-2212. [13] Jankowska AM, Makishima H, Tiu RV, et al.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A[J]. Blood,2011,118(14):3932-3941. [14] Smith AE, Mohamedali AM, Kulasekararaj A, et al.Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value[J]. Blood,2010,116(19):3923-3932. [15] Itzykson R, Solary E.An evolutionary perspective on chronic myelomonocytic leukemia[J]. Leukemia,2013,27(7):1441-1450. [16] Patnaik MM, Tefferi A.Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia[J]. Blood Cancer J,2016,6:e393. [17] Talati C, Zhang L, Shaheen G, et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis[J]. Blood,2017 Mar 30,129(13):1881-1883. [18] Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al.Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia[J]. Blood,2015,125(23):3618-3626. [19] Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood,2009,114(5):937-951. [20] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361. [21] Such E, Germing U, Malcovati L, et al.Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia[J]. Blood,2013,121(15):3005-3015. [22] Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes[J]. Leukemia,2013,27(7):1504-1510. [23] Onida F, Barosi G, Leone G, et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups[J]. Haematologica,2013 Sep,98(9):1344-1352. [24] Barosi G, Birgegard G, Finazzi G, et al.A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European Leukemia Net(ELN) consensus process[J]. Br J Haematol,2010,148(6):961-963. |
| [1] | 何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚. LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605. |
| [2] | 陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430. |
| [3] | 沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436. |
| [4] | 陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534. |
| [5] | 何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546. |
| [6] | 徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊. 实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550. |
| [7] | 赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394. |
| [8] | 郭业兵, 郑金峰. 阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407. |
| [9] | 王刚, 陈生弟. 神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4. |
| [10] | 唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17. |
| [11] | 魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7. |
| [12] | 王蔚, 王小钦. 缺铁性贫血的病因诊断[J]. 诊断学理论与实践, 2021, 20(06): 529-532. |
| [13] | 岳婧婧, 宋琦, 江旭峰, 王黎, 赵维莅, 严福华. 磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究[J]. 诊断学理论与实践, 2021, 20(06): 540-546. |
| [14] | 王昭晖, 吴海波. 胃神经鞘瘤31例临床病理学分析[J]. 诊断学理论与实践, 2021, 20(06): 552-556. |
| [15] | 王广宇, 杨昕, 张立娟, 谭姣容. 住院新诊断2型糖尿病男性患者血浆总睾酮水平与骨钙素的相关性研究[J]. 诊断学理论与实践, 2021, 20(06): 573-578. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
